The September 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Credit Suisse has set an Outperform rating and $290 price target on Amgen shares. That target implies more than 20% upside to the stock's recent trading price.
As an approved COVID-19 vaccine nears completion in terms of clinical trials, what can we expect? In the past couple of weeks, firms working toward this goal have taken steps forward and back, which...
Here is how the Dow Jones industrial average can still continue to rise and hit the 30,000 mark by year's end.
The August 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
The August 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The Dow Jones industrial average changes look a bit strange, and the real effort behind those changes may simply be to juice the index higher in the future than due to the reasons cited.
The July 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Wednesday's top analyst upgrades and downgrades included Advanced Micro Devices, Amgen, DexCom, eBay, FireEye, Kraft Heinz, 3M, Pfizer, Seagate Technology, Sonos, Starbucks and T-Mobile.
The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Goldman Sachs has seven biopharma stocks on its Conviction Buy list, and these are not all coronavirus plays. The firm thinks these stocks could go on the offensive for the rest of the year.
These four top Jefferies growth stock picks all offer investors strength in their specific industries and the ability to generate some significant portfolio alpha.
Many investors feel like the key stocks in the market have simply gotten away from them, but those fears are perhaps misguided, according to some key analysts.
Stocks were looking for direction on Monday ahead of this week’s earnings deluge. With an election coming up and with what is still a very deep recession, investors need to be considering how...